'Elbebo' MSD ' prevent vaccines against Zaire type Ebola virus
Use of Preemptive Congo, Vaccine Delivery Plan for 3Q2020
The first Ebola vaccine in the world is licensed in Europe.
European Medicines Agency has granted conditional release of the Ebola vaccine, “ Ervebo, '& # 39; which was developed by MSD, as a vaccine to prevent Ebola virus infections caused by the Zyr Ebola virus in people over 18 years.
Prior to this agreement, Elbevo was appointed for a quick review in Europe, and the European Drug Administration's Advisory Committee (CHMP) recommended conditional approval for Elbebo last month.
Elbevo has been selected for a quick FDA review in the US and is undergoing a permit review and will be approved in March next year.
After the massive Ebola outbreak in West Africa in 2014, 11,000 people died and the second deadliest Ebola incident in the Democratic Republic of Congo is reported to have killed 2,200 people. In response to this emergency, Elbevo has been used previously in Congo.
With approval, MSD plans to produce vaccines to licensed supplies from German manufacturing facilities and will be delivered in the third quarter of 2020. In addition, the company evaluates the agreement as a historical achievement, a milestone representing the power of science, innovation, and public-private partnership. It will work with Gavi, the Vaccine Alliance.
Meanwhile, Elbevo was originally developed by the National Institute of Biology of the Canadian Department of Public Health and licensed to NewLink Generics. Since then, MSD was licensed during the 2014 Ebola outbreak and has continued to develop vaccines with partners.
Copyright © Palm News Reproduction and redistribution without permission is prohibited